Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Clinical Research
  • Published:

Exposure–response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer

Abstract

Background

Abiraterone acetate is an oral 17α-hydroxylase/C17,20-lyase (CYP17) inhibitor approved for the treatment of metastatic castration-resistant prostate cancer (mCPRC) patients. Previously, a prospective observational trial demonstrated a relationship between abiraterone trough concentrations (Cmin) in plasma and treatment efficacy. The aim of our study was to investigate the exposure–response relationship of abiraterone and its metabolites, and to study if the proposed target for abiraterone of 8.4 ng/mL is feasible in a “real-world” patient cohort.

Patients and methods

mCRPC patients who had at least one abiraterone plasma concentration at steady-state were included in this study. Plasma abiraterone and its metabolites levels were analyzed using a validated liquid chromatography–mass spectrometry method. Using calculated Cmin values of abiraterone and its active metabolite Δ(4)-abiraterone (D4A), univariate, and multivariable Cox regression analyses were performed.

Results

Sixty-two patients were included in this retrospective analysis, of which 42% were underexposed (mean abiraterone Cmin ≤ 8.4 ng/mL). In multivariable analysis, Cmin ≥ 8.4 ng/mL was associated with longer prostate-specific antigen (PSA) independent progression-free survival (16.9 vs 6.1 months; p = 0.033), which resulted in a hazard ratio of 0.44 (95% confidence interval: 0.23–0.82, p = 0.01). D4A Cmin did not show a relationship with treatment efficacy.

Conclusion

Our study shows that mCRPC patients with an abiraterone Cmin ≥ 8.4 ng/mL have a better prognosis compared with patients with low Cmin. Monitoring Cmin of abiraterone can help to identify those patients at risk of suboptimal treatment for whom treatment optimization may be appropriate.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

    Article  Google Scholar 

  2. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.

    Article  CAS  Google Scholar 

  3. US Food and Drug Administration (FDA). Clinical pharmacology and biopharmaceutics review: Zytiga (abiraterone acetate). 2010;1–86. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379orig1s000clinpharmr.pdf. Accessed 17 May 2019.

  4. Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, et al. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature. 2016;533:547–51.

    Article  CAS  Google Scholar 

  5. Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015;523:347–51.

    Article  CAS  Google Scholar 

  6. Emamekhoo H, Li Z, Sharifi N. Clinical significance of D4A in prostate cancer therapy with abiraterone. Cell Cycle. 2015;14:3213–4.

    Article  CAS  Google Scholar 

  7. Hettel D, Sharifi N. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer. Nat Rev Urol. 2018;15:191–6.

    Article  CAS  Google Scholar 

  8. Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay S, et al. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. J Clin Investig. 2018;128:3333–40.

    Article  Google Scholar 

  9. Blanchet B, Carton E, Alyamani M, Golmard L, Huillard O, Thomas-Scheomann A, et al. A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients. Pharm Res. 2018;136:56–61.

    Article  CAS  Google Scholar 

  10. Carton E, Noe G, Huillard O, Golmard L, Giroux J, Cessot A, et al. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. Eur J Cancer. 2017;72:54–61.

    Article  CAS  Google Scholar 

  11. Chi KN, Spratlin J, Kollmannsberger C, North S, Pankras C, Gonzalez M, et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J Clin Pharm. 2015;55:1406–14.

    Article  CAS  Google Scholar 

  12. Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol. 2018;36:1389–95.

    Article  CAS  Google Scholar 

  13. Stover JT, Moore RA, Davis K, Harrison MR, Armstrong AJ. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2015;18:161–6.

    Article  CAS  Google Scholar 

  14. van Nuland M, Venekamp N, Wouters WME, van Rossum HH, Rosing H, Beijnen JH. LC–MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide. J Pharm Biomed Anal. 2019;170:161–8.

    Article  Google Scholar 

  15. van Nuland M, Hillebrand MJ, Rosing H, Schellens JHM, Beijnen JH. Development and validation of an LC-MS/MS method for the simultaneous quantification of abiraterone, enzalutamide, and their major metabolites in human plasma. Ther Drug Monit. 2017;39:243–51.

    Article  Google Scholar 

  16. van Nuland M, Rosing H, de Vries J, Ovaa H, Schellens JHM, Beijnen JH. An LC–MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma. J Chromatogr B. 2017;1068–1069:119–24.

    Article  Google Scholar 

  17. Stuyckens K, Saad F, Xu XS, Ryan CJ, Smith MR, Griffin TW, et al. Population pharmacokinetic analysis of abiraterone in chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2014;53:1149–60.

    Article  CAS  Google Scholar 

  18. Scher HI, Morris MJ, Stadler WM, Higano CS, Halabi S, Smith MR, et al. The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). J Clin Oncol. 2015;33:5000.

    Article  Google Scholar 

  19. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59.

    Article  Google Scholar 

  20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.

    Article  CAS  Google Scholar 

  21. Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, de Wit R, van den Bergh ACM, Coenen JLLM, et al. Differences in trial and real-world populations in the Dutch castration-resistant prostate cancer registry. Eur Urol Focus. 2018;4:694–701.

    Article  Google Scholar 

  22. Groenland SL, van Eerden RAG, Verheijen RB, Koolen SLW, Moes DJAR, Desar IME, et al. Therapeutic drug monitoring of oral anticancer drugs: the DPOG-TDM protocol for a prospective study. Ther Drug Monit. 2019;41:561–7.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. van Nuland.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van Nuland, M., Groenland, S.L., Bergman, A.M. et al. Exposure–response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 23, 244–251 (2020). https://doi.org/10.1038/s41391-019-0179-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-019-0179-5

This article is cited by

Search

Quick links